LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Trevena Inc.
Headquarters:
Chesterbrook, PA, United States
Website:
https://www.trevena.com/
Year Founded:
2007
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Carrie L. Bourdow, MBA
Number Of Employees:
N/A
Enterprise Value:
N/A
PE Ratio:
-0.03
Exchange/Ticker 1:
Pink:TRVN
Exchange/Ticker 2:
N/A
Latest Market Cap:
$1,019,300
BioCentury
|
May 1, 2025
Management Tracks
Augustine follows up venture round with pair of C-suite hires
Plus: Management changes at Cidara, Fujifilm Cellular Dynamics and Transneural
Read More
BioCentury
|
Jul 2, 2024
Management Tracks
Patricia Drake to lead commercial at Innoviva’s specialty unit
Plus: Thomas Mehrling name CEO of Swiss biotech Release, and Tenaya CSO Hoey stepping down
Read More
BioCentury
|
Jan 7, 2022
Product Development
ACTIV PPP to deliver more COVID therapy data in 2022
The ACTIV adaptive master protocols are testing a range of COVID-19 therapeutic candidates
Read More
BioCentury
|
Sep 11, 2021
Management Tracks
New CEO for Eden following conviction of JHL execs
Plus: Mavilio, Loggia join Orchard and updates from PMV, Verseau, Apexigen, VectivBio, Protagonist and more
Read More
BioCentury
|
Sep 8, 2021
Management Tracks
Exelixis executives Schwab, Berndt pass away
Plus: bluebird, ADC, Passage Bio and Insilico
Read More
BioCentury
|
Aug 13, 2020
Regulation
Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more
FDA approves a second targeted DMD therapyNS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53
Read More
BioCentury
|
Jul 25, 2020
Management Tracks
New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more
Read More
BioCentury
|
Mar 10, 2020
Product Development
March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi
Read More
BioCentury
|
Feb 29, 2020
Management Tracks
Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,
Read More
BioCentury
|
Aug 28, 2019
Company News
Aug. 28 Company Quick Takes: Amgen to appeal Repatha ruling and EcoR1 buys Woodford’s stake in Prothena; plus DarwinHealth-Celgene, CRISPR IP, Trevena and Shink
Read More
Items per page:
10
1 - 10 of 107